Kiniksa Pharmaceuticals to Report First Quarter 2022 Financial Results on May 3, 2022

Rhea-AI Summary

Kiniksa Pharmaceuticals, Ltd. (KNSA) will hold a conference call on May 3, 2022, at 8:30 a.m. Eastern Time to discuss its Q1 2022 financial results and corporate activities. A live webcast will be available on their website, with a replay accessible 48 hours post-event. Kiniksa focuses on developing therapeutic medicines for debilitating diseases, with a portfolio that includes ARCALYST®, vixarelimab, KPL-404, and mavrilimumab, targeting significant unmet medical needs through innovative biologic mechanisms.

Positive

• Kiniksa's focus on developing therapeutics for unmet medical needs.
• Portfolio includes promising assets like vixarelimab and KPL-404.

Negative

• None.

HAMILTON, Bermuda, May 02, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, May 3, 2022, at 8:30 a.m. Eastern Time to report its first quarter 2022 financial results and corporate activities.

A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. A replay of the webcast will also be available on Kiniksa’s website within approximately 48 hours of the event. The conference call can be accessed by dialing (866) 614-0636 (U.S. and Canada) or (409) 231-2053 (international) using conference ID number 7787467.

About Kiniksa
Kiniksa is a biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Kiniksa’s portfolio assets, ARCALYST^®, vixarelimab, KPL-404, and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target underserved conditions, and offer the potential for differentiation. These assets are designed to modulate immunological pathways across a spectrum of diseases. For more information, please visit www.kiniksa.com.

ARCALYST^® is a registered trademark of Regeneron Pharmaceuticals, Inc.

Every Second Counts!^®

Kiniksa Investor and Media Contact
Rachel Frank
(339) 970-9437
rfrank@kiniksa.com

FAQ

What time is Kiniksa's Q1 2022 earnings call?

Kiniksa's Q1 2022 earnings call is scheduled for May 3, 2022, at 8:30 a.m. Eastern Time.

Where can I watch Kiniksa's earnings call live?

The live webcast of Kiniksa's earnings call can be accessed on their Investors & Media section of the company's website.

What are Kiniksa's key products?

Kiniksa's key products include ARCALYST®, vixarelimab, KPL-404, and mavrilimumab.

What is the focus of Kiniksa Pharmaceuticals?

Kiniksa Pharmaceuticals focuses on developing therapeutic medicines for diseases with significant unmet medical needs.